Hengdi Pharmaceutical (301211.SZ) released its performance for the first three quarters, with net profit attributable to the parent company of 39.6578 million yuan, a year-on-year increase of 89.45%.

Zhitong Finance APP News, Hengdi Pharmaceutical (301211.SZ) released its 2026 third-quarter report. In the first three quarters, the company achieved operating revenue of 354 million yuan, a year-on-year increase of 11.14%. Net profit attributable to shareholders of the listed company was 39.6578 million yuan, a year-on-year increase of 89.45%. Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 14.3774 million yuan, a year-on-year increase of 2543.79%.